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The Anyplex II HPV28 (H28; Seegene) is a new semiquantitative real-timemultiplex PCR assay for screening and genotyping 28
human papillomaviruses (HPV) in only 2 reaction wells. H28 was compared to the PGMY-CHUV assay (PG) with 309 archival
DNA samples from cervical smears collected over 8 years in our laboratory. H28 and PG were fully concordant at the genotypic
level on 228 (73.8%) out of 309 samples: 27 HPV negative and 201 HPV positive. The 201 fully concordant positive samples cor-
responded to single infections (n 145) and to multiple infections (2 genotypes, n 38; 3 to 5 genotypes, n 18). The remain-
ing 81 samples (26.2%) were either partially concordant (n 64, 20.7%) or fully discordant (n 17, 5.5%). While genotype-spe-
cific agreement was nearly perfect ( 0.877), HPV51 was significantly less well detected by H28 and the converse was observed
for HPV40, -42, -54, and -68. Sequencing of PG amplicons confirmed HPV51 discordants and suggested the involvement of a
possibly local HPV51 subtype. Mismatches in the PGMY09 primers to HPV68a explainedmost of the HPV68 discordants, con-
firming the specificity of H28 toward HPV68.With PG as a reference, the sensitivity and specificity of H28 were 93.4% and
99.0%, respectively. Considering H28 as a reference, the sensitivity and specificity of PG were 83.8% and 99.6%, respectively. H28
is a very sensitive and specific HPV genotyping assay suitable for research and clinical use as an adjunct to a clinically validated
test. H28 semiquantitative readout ought to be evaluated for primary cervical cancer screening.
High-risk human papillomaviruses (HPV) are the causativeagents of cervical cancer (1, 2). Molecular detection of high-
risk HPV in cervical smears therefore is used as an adjunct to
cytology to identify women at risk for cervical cancer (3–5). Assays
that have been clinically validated identify high-risk genotypes as a
whole (the hybrid capture II [HCII] assay) or distinguish HPV16
or HPV18 from the other high-risk types as a group (HPV31, -33,
-35, -39, -45, -51, -52, -56, -58, -59, -66, and -68) (Abbott Real-
Time high-risk HPV and Roche Cobas 4800 HPV tests). The
Abbott and Roche tests have been validated against HCII using
cervical intraepithelial neoplasia (CIN) grade 2 or higher as end-
points (6–8). They were also found in these studies to be suitable
for primary cervical cancer screening according to published
guidelines (9).
In contrast to the clinical application of partial genotyping ex-
emplified by the Abbott and Roche assays mentioned above, com-
prehensive HPV genotyping is essential in epidemiology and for
vaccine surveillance (10). Full HPV genotyping is also useful clin-
ically to identify patients with persisting, type-specific high-risk
HPV infections which are known to confer a higher risk of cancer
progression than incident infections by the same high-risk type
(11). Many published HPV genotyping assays rely on endpoint
multiplex PCR followed by reverse hybridization against a panel
of type-specific probes immobilized on membranes or beads (12–
19). They target at least 25 genotypes: the 14 high-risk HPV geno-
types, indicated above, as well as low-risk (HPV6, -11, -42, -44,
-53, -54, and -70) or potentially high-risk (HPV26, -69, -73, and
-82) genotypes. These assays, including ours, are time-consuming
and necessitate some degree of expertise (20). Owing to their ease
of use and objective readout, real-time PCR assays capable of de-
tecting a higher number of HPV genotypes are desirable. Such
coverage by real-time PCR is, however, challenging. Thus, pub-
lished multiplex real-time PCR assays for HPV genotyping need at
least 6 different PCR wells per sample to overcome the limitations
of present chemistries and equipment, which distinguish at best 3
to 5 targets per well (21).
Seegene recently commercialized the real-time PCR Anyplex II
HPV28 kit (H28). H28 is aimed at genotyping 28 HPV in only 2
PCR wells per sample. This system therefore has the potential to
greatly simplify HPV genotyping. For this reason, we decided to
compare H28 with our in-house PGMY-CHUV (PG) assay de-
scribed in Chapter 5 of the WHO HPV Laboratory Manual (10).
PG has been found to be highly comparable to the commercially
available linear array (LA; Roche) with some advantages in terms
of sensitivity and specificity toward HPV56 and HPV52 (20). PG
has also been repeatedly proficient in several laboratories within
the WHO HPV Laboratory Network at frequencies at least as good
as those of LA (22).
We show here that the present version of H28 overall is more
sensitive than and as specific as PG. Among the high-risk geno-
types, H28 detected significantly fewer cases of HPV51, possibly in
a locally prevalent and subtype-dependent manner, and more
cases of HPV68. The latter is a known consequence of the inability
of the PGMY primers to efficiently target the HPV68a subtype
(23). Supplementing PG with an additional set of an HPV68a-
specific primer/probe corrected this defect, confirming the speci-
ficity of H28 toward HPV68.
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MATERIALS AND METHODS
Samples. (i) Cervical smear DNA. A total of 298 DNA samples from our
biobank were selected from all gynecological patients who submitted
more than one cervical smear to our laboratory from May 1999 till De-
cember 2012 and who tested HPV positive at least once. An additional
subset of 14 samples was also randomly selected among HPV-negative
women with atypical squamous cells of undetermined significance (ASC-
US). These DNA samples had been purified using MagNApure chemistry
(Roche, Rotkreuz, Switzerland) as previously described (20).
A single sample was evaluated from each patient to increase genotype/
subtype diversity. Out of the 312 samples, 3 were lost during storage, so
309 samples (99%) were left to be compared. These 309 samples repre-
sented 162 ASC-US, 80 low-grade squamous intraepithelial lesion (LSIL),
53 normal, and 14 high-grade squamous intraepithelial lesion (HSIL)
samples. This mode of selection enriched for positives to ensure sufficient
numbers of individual genotypes for statistical analysis.
(ii) WHO quality control panel. The 2011 WHO HPV proficiency
panel was provided by EQUALIS AB (Uppsala, Sweden). It consisted of 43
DNA samples and of 3 cell samples. Only the DNA samples were tested
with H28. They corresponded to single and to multiple infections con-
taining 5 to 500 viral genome equivalents per reaction (5 l DNA per
reaction). The genomes represented in this panel were HPV6, -11, -16,
-18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68a, and -68b.
(iii) Ethical issues. This study was approved by our local ethics com-
mittee.
PGMY-CHUV assay (PG). PCR using the PGMY primers and reverse
blotting hybridization (RBH) were performed as described in Chapter 5 of
the WHOHPVLaboratoryManual and its validation study with 5l DNA
in a single 50-l PCR mixture containing 3 mM MgCl2 (10, 20). This assay
allows genotyping of 31 HPV (6, 11, 16, 18, 26, 31, 33, 34, 35, 39, 40, 42, 44,
45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 66, 68 [ME180, b subtype], 69, 70, 73,
82, 83, and 84).
Version 2 of PG (PGv2) was designed to resolve HPV68-discordant
cases. Compared to PG, it uses an additional HPV68a-specific primer
(RSMY09-L, 5=-CGTCCTAATGGGAATTGGTC-3=) at 80 nM and an
HPV68a-specific probe (5=-CTGATTGTAGGTAGCGGTATG-3=).
Anyplex IIHPV28.H28 was performed as recommended by the man-
ufacturer (Seegene, Seoul, South Korea) with 5l DNA in each of the two
20-l reaction mixtures with primer set A or B. H28 uses HPV-specific
dual priming oligonucleotides (DPO) for multiplex (real-time) PCR (24).
In addition, it uses a primary HPV type-specific probe (pitcher) carrying
an artificial 5= extension and a secondary, artificial, fluorescently labeled
probe (catcher) specific to each pitcher. For a given HPV, the catcher is
activated by the pitcher’s 5= extension oligonucleotide upon its release
from the bound pitcher by the exonucleolytic activity of the polymerase.
The 5= extension is complementary to the 3= end of the matched catcher.
Its binding to the catcher primes DNA synthesis by the polymerase and
conversion of the single-stranded catcher to a double-stranded form with
concomitant release of quenching and emission of fluorescence. The
catchers are labeled with a common fluorophore for a given set of 3 geno-
types. Each catcher, and hence its corresponding HPV, can be distin-
guished from the others sharing the same fluorophore by melting curve
analysis at 3 specific steps during the real-time PCR. Since the catchers are
totally artificial, their melting temperatures can be well defined and attrib-
uted to the HPV type that each catcher represents. This design constitutes
the TOCE system, which has already been implemented for the detection
of respiratory viruses (25). In addition, knowledge of the step at which the
melting curve becomes positive allows us to semiquantify the viral load,
from low (; positive after 40 PCR cycles), to intermediate (; positive
within 31 to 39 cycles), to high (; positive before 31 cycles). H28
thus distinguishes semiquantitatively 28 HPV genotypes (6, 11, 16, 18, 26,
31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 66, 68, 69, 70,
73, and 82) in only 2 reactions by taking advantage of the 5 dyes that can
be resolved on the CFX96 real-time PCR instrument (Bio-Rad; provided
together with the H28 kits by BU¨HLMANN Laboratories AG, Schönen-
buch, Switzerland). Data recording and interpretation were automated
with the Seegene viewer software according to the manufacturer’s instruc-
tions.
DNA sequencing and phylogenetic analysis. HPV51- and HPV68-
discordant cases were assessed by DNA sequencing of PG amplicons and
comparison to the nonredundant nucleic acid GenBank database as de-
scribed in Estrade et al. (20). DNA sequencing was also performed with
the HMB01 primer for HPV51 (13).
Phylogenetic analysis of HPV51 PG amplicons was performed with
the tree builder tool of Geneious (Geneious version 7.0.5; Biomatters
LTD, New Zealand) using an HPV16 PG amplicon (GenBank accession
number AF003027) as an outgroup with 1,000 replicates. The noninfor-
mative PGMY primer sequences were removed from the amplicon se-
quences prior to alignment and tree building.
Data analysis and statistics. Despite selecting the most recent sample
from each patient, some had been stored at20°C for up to 8 years until
reanalysis. PG therefore was repeated simultaneously with H28. PG re-
sults were then compared with H28 using correspondence queries in Mi-
crosoft Access. For statistics, the genotypes were restricted to the 26 shared
by both assays: 18 high risk (HPV16, -18, -26, -31, -33, -35, -39, -45, -51,
-52, -56, -58, -59, -66, -68, -69, -73, and -82) and 8 low risk (HPV6, -11,
-40, -42, -44, -53, -54, and -70). Risk attribution of HPV genotypes was
according to Estrade et al. (20).
Tables for statistics were generated with Microsoft Access or Excel, and
statistics were performed with GraphPad Prism (GraphPad Software, La
Jolla, CA). Agreement of HPV typing results between paired cases was
evaluated with the Cohen’s kappa () statistics and their uneven distribu-
tion evaluated with McNemar’s test. Agreement was interpreted as poor
(  0.200), weak (0.200    0.401), moderate (0.400    0.601),
strong (0.600 0.801), near perfect (0.800 1.000), and perfect
(  1.000). Statistics for unpaired cases were performed with the two-
sided Fisher’s exact test using 2-by-2 contingency tables. The trend of
association between viral load and discordance was evaluated with the
chi-square test for trend.
Nucleotide sequence accession numbers. The 10 HPV51 amplicon
sequences are referenced in GenBank with the accession numbers
KF707617 to KF707626.
RESULTS
Evaluation of H28 with the 2011 quality control panel from
WHO. All 43 DNA samples were correctly identified by H28 (not
shown; sensitivity and specificity of 100%). H28 therefore was
proficient for the genotyping of the 17 HPV types and subtypes
represented in this panel, including those at the lowest concentra-
tion of 5 to 50 viral genome equivalents per reaction. Two geno-
type-sample combinations were missed by PG in comparison
(HPV18 at 5 copies per reaction, single infection; HPV31 at 50
copies per reaction, multiple infections). PG was not proficient
only for HPV68a, which cannot be efficiently detected with the
PGMY primers (23).
Evaluation of H28 with PG. After restricting the analysis
to the 26 genotypes shared by H28 and PG, 293 samples out of
309 were concordantly screened by both assays as HPV positive
(n 266) or as HPV negative (n 27), and 16 were discordant
(agreement 94.8%;   0.742, considered strong) (Table 1).
A total of 282 samples were recorded positive by either assay.
Of them, 201 (71.3%) were fully concordant at the genotypic
level, even with multiple infections containing up to 5 geno-
types (single infections, n  145 samples; double infections,
n  38 samples; 3 to 5 genotypes, n  18 samples), 64 were
partially concordant (double infections, n 32 samples; 3 to 8
genotypes, n  32 samples), and 17 were fully discordant.
Among the 17 fully discordant samples, 6 H28-negative sam-
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ples were recorded as single infections by PG (HPV51, n  4
samples; HPV53 and HPV70, n  1 sample each), 10 PG-neg-
ative samples were recorded as single infection (n 8 samples;
HPV18, -40, -45, -53, -54 twice, -56, -68) or double infections
(n  2 samples; HPV16 and -53, HPV42 and -68) by H28, and
1 was fully discordant among the 266 H28/PG-positive samples
(HPV82 with PG and HPV59 with H28).
The genotype-specific comparison of H28 with PG is presented
in Table 2. While the agreement was nearly perfect (total, 98.71%;
  0.877) considering all 26 genotypes, there was a statistically
significant higher number of genotype-sample combinations
found by H28 that were not found by PG (n 76) than of those
found by PG and not by H28 (n  28, P  0.0001). This was
contributed mainly by the low-risk viruses (total L, 7 versus 38,
P 0.0001, agreement 98.18%,  0.826) in comparison with
the high-risk viruses (total H, 21 versus 38, P  0.0372, agree-
ment 98.94%,  0.899). Consistent with this observation, the
proportion of concordant genotype-sample combinations from
the high-risk group (280/339) was significantly higher (P 
0.0065, by Fisher’s exact test) than from the low-risk group (114/
159). Individually, the majority of genotypes exhibited agreement
values above 99%, except HPV40, -42, -51, -53, -54, -56, -58, -66,
TABLE 1 Comparison of H28 and PG for screening HPV-positive and
HPV-negative casesa
PG result
No. of samples by
H28 result
Total no. of samplesNEG POS
NEG 27 10 37
POS 6 266 272
Total 33 276 309
a PG, PGMY-CHUV; H28, Anyplex HPV28; NEG, negative; POS, positive. A test was
considered HPV positive if it was positive for at least one of the 26 genotypes shared by
both assays (see Materials and Methods). Agreement, 293/309 94.8%;   0.742,
considered as a strong agreement; P 0.453 (McNemar).
TABLE 2 Genotype-specific comparison of H28 and PGf
Genotypea Riskb
No. of genotype-sample combinationsc
% agreement  SD Int.d McNemar value/ / / /
6 L 297 1 2 9 99.03 0.852 0.084 np 1.000
11 L 302 0 1 6 99.68 0.921 0.078 np 1.000
16 H 260 2 1 46 99.03 0.963 0.021 np 1.000
18 H 288 2 1 18 99.03 0.918 0.047 np 1.000
26 H 308 0 0 1 100.00 1.000 0.000 pe 1.000
31 H 281 0 1 27 99.68 0.980 0.020 np 1.000
33 H 296 0 0 13 100.00 1.000 0.000 pe 1.000
35 H 300 0 3 6 99.03 0.795 0.115 st 0.248
39 H 294 0 1 14 99.68 0.964 0.036 np 1.000
40 L 301 0 7 1 97.73 0.218 0.182 we 0.023e
42 L 267 1 10 31 96.44 0.829 0.050 np 0.016e
44 L 293 0 1 15 99.68 0.966 0.034 np 1.000
45 H 294 2 1 12 99.03 0.884 0.06 np 1.000
51 H 286 10 0 13 96.76 0.706 0.087 st 0.004e
52 H 281 2 0 26 99.35 0.959 0.029 np 0.480
53 L 269 2 6 32 97.41 0.874 0.044 np 0.289
54 L 287 1 10 11 96.44 0.649 0.098 st 0.016e
56 H 285 0 4 20 98.71 0.902 0.048 np 0.134
58 H 284 0 5 20 98.38 0.880 0.053 np 0.074
59 H 298 1 1 9 99.35 0.897 0.072 np 1.000
66 H 288 1 4 16 98.38 0.856 0.063 np 0.371
68 H 281 0 13 15 95.79 0.677 0.083 st 0.001e
69 H 308 0 0 1 100.00 1.000 1.000 pe 1.000
70 L 297 2 1 9 99.03 0.852 0.084 np 1.000
73 H 295 0 3 11 99.03 0.875 0.071 np 0.2482
82 H 296 1 0 12 99.68 0.958 0.042 np 1.000
Total
High and low risk 7,536 28 76 394 98.71 0.877 0.012 np 0.0001e
High risk 5,223 21 38 280 98.94 0.899 0.013 np 0.0372e
Low risk 2,313 7 38 114 98.18 0.826 0.025 np 0.0001e
a Only the 26 genotypes shared by both assays were considered for analysis.
b L, low risk; H, high risk.
c/, negative with both assays;/, H28 negative and PG positive;/, H28 positive and PG negative;/: positive with both assays.
d Interpretation of the kappa values. we, weak; st, strong; np, near perfect; pe, perfect.
e P 0.05, two-sided McNemar’s test.
f The total number of samples was 309, giving 8,034 genotype-sample combinations. PG, PGMY-CHUV; H28, Anyplex HPV28. Sensitivity of H28 using PG as a reference,
394/422 93.4%; specificity of H28 using PG as a reference, 7,536/7,612 99.0%; sensitivity of PG using H28 as a reference, 394/470 83.8%; specificity of PG using H28 as a
reference, 7,536/7,564 99.6%.
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and -68. Of those, HPV40, -42, -54, and -68 were significantly
more frequently detected by H28 (P  0.05), while the converse
was true for HPV51 (P  0.004). Using PG as a reference, the
sensitivity and specificity of H28 at the genotypic level were 93.4%
and 99.0%, respectively.
Discordance analysis was restricted to the significantly affected
genotypes and for two variables: the infection status (multiple
versus single infections) and the viral load (20). Among the low-
risk genotypes, HPV42 was the only one displaying a significant
association between discordance and the sample’s multiple infec-
tion status (Table 3). A trend for discordance was associated with
lower viral loads for HPV40, -42, and 54 (Table 4). No trend was
noticed for HPV51 and -68.
For HPV51, all discordants exhibited medium (n 6) to high
(n 4) viral loads (Table 4). Sequencing analysis of the 4 discor-
dant single infections and of the 6 concordant single infections
confirmed this genotype (Table 3). Phylogenetic analysis indi-
cated that 3 of the 4 discordants clustered as a distinct subtype
among the 10 HPV51 cases (data not shown).
For HPV68, 8 out of the 13 discordant cases were identified as
HPV68a by PGv2 (see Materials and Methods), 3 remained
HPV68 negative, and 2 were not assessed with PGv2, as they were
positive for HPV68b as determined originally with PG. The
HPV68a single infection identified with PGv2 could be confirmed
by DNA sequencing (Table 3).
There was no systematic association of two genotypes during
the course of this study with either assay, even with high viral loads
as judged by the H28 semiquantitative report and by the PG PCR/
RBH signal strengths (not shown). This evaluation therefore sup-
ports that H28 is more sensitive rather than less specific than PG
for HPV40, -42, -54, and -68 and by extension for other genotypes
with the exception of HPV51. Using H28 as a reference, the sen-
sitivity and specificity of PG at the genotypic level were 83.8% and
99.6%, respectively (Table 2).
DISCUSSION
Overall, H28 performed very similarly to PG. However, H28 de-
tected more positives, suggesting that it truly is more sensitive
than PG. This conclusion is supported by H28 correct identifica-
tion of all genotypes even at the lowest concentration (5 to 50 viral
genome equivalents per reaction) in the 2011 WHO proficiency
panel samples and in the 2013 panel (S. A. Nordbø, personal com-
munication). Although it was proficient with both panels, PG was
in comparison less sensitive in 3 samples involving HPV18 (5
genome equivalents, 2011 panel), HPV31 (50 genome equiva-
lents, 2011 panel), and HPV56 (50 genome equivalents, 2013
panel).
Higher sensitivity rather than lower specificity of H28 was also
supported by its not recording systematic double infections in-
volving the same genotypes during this work. Based on these re-
sults, we concluded that the H28-positive/PG-negative results
were indeed true positives. It therefore seemed reasonable to also
consider H28 as a reference against which to compare PG. Under
this condition, the sensitivity of PG was lower, at 83.8% (versus
93.4% for H28 using PG as a reference), and the specificity was
slightly higher, at 99.6% (versus 99.0%). Enrichment of samples
from patients known to have been positive at least once by PG
introduced a selection bias that may have lessened the difference
in sensitivity between H28 and PG. This selection bias was mini-
mal, however, considering that more than 67% of the genotype-
sample combinations (not shown) were contributed by multiple
infections (42%, not shown), which were more likely to be re-
corded as HPV positives independently of the assay.
The reevaluation of the HPV51 discordants confirmed our results
except for one case, which could not be amplified on retesting at
Seegene using different PCR assays. This sample (R50) was recorded
as weakly positive by PG with stochastic amplification. In contrast,
the remaining 3 HPV51 subtypes from discordant single infections
clustered phylogenetically and exhibited mismatches affecting the
H28 primers/probe (Seegene, personal communication). These
HPV51 subtypes were not represented in nucleic acid databases. They
therefore were likely to be suboptimally detected by H28, whose sen-
sitivity relies on type-specific primers and probes strictly adapted to
published sequences (25). It remains to be determined, however,
TABLE 4 Distribution of HPV40, -42, -54, -51, and -68 according to
viral load
Genotype Riskd
No. of samples by viral loada
Pb
  
Disc. Conc. Disc. Conc. Disc. Conc.
40 L 3 0 4 0 0 1 0.0434c
42 L 3 0 7 15 1 16 0.0010c
54 L 9 1 2 9 0 1 0.0009c
51 H 0 2 6 7 4 4 0.3339
68 H 3 3 9 5 1 7 0.1147
a, positive within 41 to 50 cycles;, positive within 31 to 40 cycles;, positive
before 31 cycles by H28 for H28-positive cases. Weak or stochastic (), medium (),
or strong () PCR/RBH signal by PG for H28-negative cases (20). The numbers
indicated are pooled from single and multiple infections. Disc., number of discordant
cases; Conc., number of concordant cases.
b Chi-square analysis for trend addressing whether discordance is associated with viral
load.
c P 0.05.
d L, low risk; H, high risk.
TABLE 3 Distribution of HPV40, -42, -54, -51, and -68 according to the
infection status
Genotype Riskg
No. of casesa
Pb
Single infection
Multiple
infections
Disc. Conc. Disc. Conc.
40 L 1 0 6 1 1
42 L 0 16 11 15 0.0027f
54 L 2 1 9 10 1
51 H 4c 6d 6 7 1
68 H 1 5 12e 10 0.1727
a The infection status (single versus multiple) was attributed after combining PG and
H28 results. Disc., number of discordant cases; Conc., number of concordant cases.
b Fisher’s two-tailed P value addressing whether discordance is associated with the
infection status.
c All fully discordant cases (samples R18, R50, R72, and R289) were confirmed as
HPV51 by DNA sequencing.
d All fully concordant cases (samples R11, R60, R155, R216, R253, and R283) were
confirmed as HPV51 by DNA sequencing.
e Of which one fully discordant case (sample R122, HPV42 and HPV68 by H28) was
identified as a single HPV68a infection by PGv2 and DNA sequencing.
f P 0.05.
g L, low risk; H, high risk.
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whether the H28 false-negative HPV51 subtypes are specific to our
study population or distributed worldwide.
The PGMY primers used in PG are degenerate to identify po-
tentially unknown genotypes (13). Broad-range detection benefits
from this approach at the cost of sensitivity, especially with low
viral loads in multiple infections (20). The trends for discordance
with low viral loads and with multiple-infection status between
PG and H28 regarding HPV40, -42, and -54 are in line with PGMY
degeneracy. At the extreme, the lack of sensitivity of PGMY-based
assays toward HPV68a is due to three mismatches within the
PGMY09-L primer, as determined by DNA sequencing of a rare
HPV68a PG-positive case from our biobank. This observation
allowed designing the HPV68a-specific RSMY09-L primer used in
PGv2. PGv2 is currently under prospective validation to ensure
that RSMY09-L does not negatively affect the detection of other
genotypes. At the time of manuscript submission, PGv2 was not
inferior to PG for HPV genotyping (n 315 samples, of which 7
contained HPV68a). PGv2 was, in addition, fully proficient with
the 2013 WHO quality control panel, including HPV68a (not
shown). The limitation of PGMY-based HPV genotyping assays
regarding HPV68a should be taken into account for data evalua-
tion comparing the pre- and postvaccination eras, especially when
addressing type replacement possibly involving HPV68.
H28 thus appears very efficient for epidemiological studies us-
ing fresh cervical smears. Like PG, it is, however, too sensitive for
clinical purposes, if not used as an adjunct to a clinically validated
assay. The locations of the H28 primers/probes within the HPV
genomes are Seegene’s proprietary information. It therefore is im-
possible to predict whether this assay would be suitable for epide-
miological studies using fixed and paraffin-embedded high-grade
tumor material, since sensitivity may be affected by the size and
genomic location of the amplicons (26). Validation of H28 with
such samples therefore would be of interest. Clinical evaluation of
H28 with CIN2 and more (CIN2) or CIN3 endpoints would
also be of interest, because the semiquantitative readout that its
technology allows may be suitable for primary cervical cancer
screening using clinically relevant HPV genotype-specific detec-
tion thresholds (27). If feasible, H28 would address not only HPV
type-specific persistence but also clinically relevant infections.
In conclusion, H28 is a very sensitive and specific HPV screen-
ing and genotyping assay which may simplify and standardize
HPV genotyping. It requires less manpower and expertise than PG
or other assays based on reverse hybridization and could be used
for large-scale testing thanks to its automation capacity and ob-
jective reading.
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ADDENDUM IN PROOF
Seegene now offers a research-use-only (RUO) kit for detection of
the HPV51 subtypes that were missed by H28.
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